Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study

Journal of Hepatology

Volumn 62, Issue 1, 2015, Pages 56-63

  Zoulim, Fabien ^a   Carosi, Giampiero ^b   Greenbloom, Susan ^c   Mazur, Wlodzimierz ^d   Nguyen, Tuan ^e   Jeffers, Lennox ^f   Brunetto, Maurizia ^g   Yu, Song ^h   Llamoso, Cyril ^h  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITY OF BRESCIA   (Italy)

^c Toronto Digestive Disease Associates   (Canada)

^d MEDICAL UNIVERSITY OF SILESIA   (Poland)

^e Alvarado Hospital Medical Center   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY HOSPITAL OF PISA   (Italy)

^h BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; TENOFOVIR; ANTIVIRUS AGENT; GUANINE; VIRUS DNA;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN DETECTION; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS GENOTYPE A; HEPATITIS B VIRUS GENOTYPE C; HEPATITIS B VIRUS GENOTYPE D; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); OPEN STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; FEMALE; FOLLOW UP; GENETICS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; IMMUNOLOGY; MALE; MIDDLE AGED; MULTICENTER STUDY; VIROLOGY;

ANTIVIRAL AGENTS; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; GUANINE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; TENOFOVIR;

EID: 84918514643     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.08.031     Document Type: Article

References (50)

1. Y.F. Liaw, J.H. Kao, T. Piratvisuth, H.L.Y. Chan, R.N. Chien, and C.J. Liu Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update Hepatol Int 6 2012 531 561
2. European Association for the Study of the Liver EASL clinical practice guidelines: management of chronic hepatitis B virus infection J Hepatol 57 2012 167 185
3. A.S. Lok, and B.J. McMahon Chronic hepatitis B: update 2009 Hepatology 50 2009 661 662
4. C.J. Chen, H.I. Yang, and U.H. Iloeje REVEAL-HBV Study Group. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B Hepatology 49 2009 S72 S84
5. J.E. Newbold, H. Xin, M. Tencza, G. Sherman, J. Dean, and S. Bowden The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes J Virol 69 1995 3350 3357
6. T. Nguyen, P. Desmond, and S. Locarnini The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B Hepatol Int 3 2009 5 15
7. A.J. Thompson, T. Nguyen, D. Iser, A. Ayres, K. Jackson, and M. Littlejohn Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers Hepatology 51 2010 1933 1944
8. B. Werle-Lapostolle, S. Bowden, S. Locarnini, K. Wursthorn, J. Petersen, and G. Lau Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy Gastroenterology 126 2004 1750 1758
9. C. Pichoud, F. Berby, L. Stuyver, M.A. Petit, C. Trepo, and F. Zoulim Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B J Hepatol 32 2000 307 316
10. H.L. Janssen, M. van Zonneveld, H. Senturk, S. Zeuzem, U.S. Akarca, and Y. Cakaloglu Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial Lancet 365 2005 123 129
11. G.K. Lau, T. Piratvisuth, K.X. Luo, P. Marcellin, S. Thongsawat, and G. Cooksley Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B N Engl J Med 352 2005 2682 2695
12. H.L. Janssen, C.J. Kerhof-Los, R.A. Heijtink, and S.W. Schalm Measurement of HBsAg to monitor hepatitis B viral replication in patients on alpha-interferon therapy Antiviral Res 23 1994 251 257
13. K. Wursthorn, M. Lutgehetmann, M. Dandri, T. Volz, P. Buggisch, and B. Zollner Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B Hepatology 44 2006 675 684
14. H.L. Chan, V.W. Wong, A.M. Tse, C.H. Tse, A.M. Chim, and H.Y. Chan Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response Clin Gastroenterol Hepatol 5 2007 1462 1468
15. M.J. Sonneveld, V. Rijckborst, C.A. Boucher, B.E. Hansen, and H.L. Janssen Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline Hepatology 52 2010 1251 1257
16. M.R. Brunetto, F. Moriconi, F. Bonino, G.K. Lau, P. Farci, and C. Yurdaydin Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B Hepatology 49 2009 1141 1150
17. E.K. Manesis, E.S. Hadziyannis, O.P. Angelopoulou, and S.J. Hadziyannis Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels Antivir Ther 12 2007 73 82
18. R. Zoutendijk, B.E. Hansen, A.J. van Vuuren, C.A. Boucher, and H.L. Janssen Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss J Infect Dis 204 2011 415 418
19. R. Gish, T.T. Chang, C.L. Lai, R.A. de Man, A. Gadano, and C. Llamoso Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive, nucleoside-naive patients treated with entecavir Antivir Ther 18 2013 691 698
20. M.H. Lee, M. Lee da, S.S. Kim, J.Y. Cheong, and S.W. Cho Correlation of serum hepatitis B surface antigen level with response to entecavir in naive patients with chronic hepatitis B J Med Virol 83 2011 1178 1186
21. J.G. Reijnders, V. Rijckborst, M.J. Sonneveld, S.M. Scherbeijn, C.A. Boucher, and B.E. Hansen Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir J Hepatol 54 2011 449 454
22. J. Fung, C.L. Lai, J. Young, D.K. Wong, J. Yuen, and W.K. Seto Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment Am J Gastroenterol 106 2011 1766 1773
23. J.W. Shin, S.W. Jung, B.R. Park, C.J. Kim, J.B. Eum, and B.G. Kim Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg, and HBV DNA levels J Viral Hepat 19 2012 724 731
24. H.L. Chan, A. Thompson, M. Martinot-Peignoux, T. Piratvisuth, M. Cornberg, and M.R. Brunetto Hepatitis B surface antigen quantification: why and how to use it in 2011 - A core group report J Hepatol 55 2011 1121 1131
25. T.T. Chang, R.G. Gish, R. de Man, A. Gadano, J. Sollano, and Y.C. Chao A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B N Engl J Med 354 2006 1001 1010
26. C.L. Lai, D. Shouval, A.S. Lok, T.T. Chang, H. Cheinquer, and Z. Goodman Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B N Engl J Med 354 2006 1011 1020
27. P. Marcellin, E.J. Heathcote, M. Buti, E. Gane, R.A. de Man, and Z. Krastev Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B N Engl J Med 359 2008 2442 2455
28. P. Marcellin, E. Gane, M. Buti, N. Afdhal, W. Sievert, and I.M. Jacobson Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study Lancet 381 2012 468 475
29. T.T. Chang, C.L. Lai, Y.S. Kew, S.S. Lee, H.S. Coelho, and F.J. Carrilho Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B Hepatology 51 2010 422 430
30. T.T. Chang, Y.F. Liaw, S.S. Wu, E. Schiff, K.H. Han, and C.L. Lai Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B Hepatology 52 2010 886 893
31. R. Zoutendijk, J.G. Reijnders, F. Zoulim, A. Brown, D.J. Mutimer, and K. Deterding Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis Gut 62 2013 760 765
32. T. Hosaka, F. Suzuki, M. Kobayashi, Y. Seko, Y. Kawamura, and H. Sezaki Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection Hepatology 58 2013 98 107
33. D.J. Tenney, R.E. Rose, C.J. Baldick, K.A. Pokornowski, B.J. Eggers, and J. Fang Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy Hepatology 49 2009 1503 1514
34. A. Snow-Lampart, B. Chappell, M. Curtis, Y. Zhu, F. Myrick, and J. Schawalder No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus Hepatology 53 2011 763 773
35. M.P. Manns, U.S. Akarca, T.T. Chang, W. Sievert, S.K. Yoon, and N. Tsai Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901 Expert Opin Drug Saf 11 2012 361 368
36. E.J. Heathcote, P. Marcellin, M. Buti, E. Gane, R.A. de Man, and Z. Krastev Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B Gastroenterology 140 2011 132 143
37. A.S. Lok, H. Trinh, G. Carosi, U.S. Akarca, A. Gadano, and F. Habersetzer Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B Gastroenterology 143 2012 e1
38. K. Wursthorn, M. Jung, A. Riva, Z.D. Goodman, P. Lopez, and W. Bao Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients Hepatology 52 2010 1611 1620
39. P. Marcellin, E.J. Heathcote, M. Buti, Z. Krastev, I. Jacobson, and R.A. de man HBsAg kinetics in patients with chronic hepatitis B (CHB) treated with tenofovir disoproxil fumarate (TDF) for up to 4 years J Hepatol 54 2011 S297 abstract 740
40. J. Jaroszewicz, H. Ho, A. Markova, K. Deterding, K. Wursthorn, and S. Schulz Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues Antivir Ther 16 2011 915 924
41. W.K. Seto, D.K. Wong, J. Fung, F.Y. Huang, C.L. Lai, and M.F. Yuen Reduction of hepatitis B surface antigen levels and HBsAg seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy Hepatology 58 2013 923 931
42. W.K. Seto, K. Liu, D.K. Wong, J. Fung, F.Y. Huang, and I.F. Hung Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment J Hepatol 59 2013 706 716
43. M.R. Brunetto, P. Marcellin, B. Cherubini, C. Yurdaydin, P. Farci, and S.J. Hadziyannis Response to peginterferon alfa-2a (40 KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype J Hepatol 59 2013 1153 1159
44. M. Sugiyama, Y. Tanaka, T. Kato, E. Orito, and K. Ito Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and anti-gens Hepatology 44 2006 915 924
45. D.K. Wong, W.K. Seto, J. Fung, P. Ip, F.Y. Huang, and C.L. Lai Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency Clin Gastroenterol Hepatol 11 2013 1004 1010
46. J.M. Lee, S.H. Ahn, H.S. Kim, H. Park, H.Y. Chang, and Y. Kim do Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir Hepatology 53 2011 1486 1493
47. Y.K. Jung, J.H. Kim, Y.S. Lee, H.J. Lee, E. Yoon, and E.S. Jung Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naive, hepatitis B e antigen-positive patients receiving entecavir J Clin Gastroenterol 44 2010 653 657
48. R.P. Perrillo, C.L. Lai, Y.F. Liaw, E.R. Schiff, S.W. Schalm, and E.J. Heathcote Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B Hepatology 36 2002 186 194
49. O. Borgniet, P. Parvaz, C. Bouix, P. Chevallier, C. Trepo, and P. Andre Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B J Med Virol 81 2009 1336 1342
50. S. Chevaliez, C. Hézode, S. Bahrami, M. Grare, and J.M. Pawlotsky Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely J Hepatol 58 2013 676 683